The efficacy and safety of daily rituximab in patients with systemic rheumatoid vasculitis has been examined based on data from 17 patients enrolled on the French AutoImmunity and Rituximab registry. After 6 months of treatment, 12 patients achieved complete remission of their vasculitis. However, maintenance therapy with rituximab might be necessary to prevent relapse: in 2 out of 3 patients who relapsed when rituximab was discontinued (from a total of 9 relapses), remission was re-established when the drug was reintroduced.